Altered molecular specificity of surfactant phosphatidycholine synthesis in patients with acute respiratory distress syndrome
Ahilanandan Dushianthan, Victoria Goss, Rebecca Cusack, Michael P W Grocott, Anthony D Postle, Ahilanandan Dushianthan, Victoria Goss, Rebecca Cusack, Michael P W Grocott, Anthony D Postle
Abstract
Background: Acute respiratory distress syndrome (ARDS) is a life-threatening critical illness, characterised by qualitative and quantitative surfactant compositional changes associated with premature airway collapse, gas-exchange abnormalities and acute hypoxic respiratory failure. The underlying mechanisms for this dysregulation in surfactant metabolisms are not fully explored. Lack of therapeutic benefits from clinical trials, highlight the importance of detailed in-vivo analysis and characterisation of ARDS patients according to patterns of surfactant synthesis and metabolism.
Methods: Ten patients with moderate to severe ARDS were recruited. Most (90%) suffered from pneumonia. They had an infusion of methyl-D9-choline chloride and small volume bronchoalveolar lavage fluid (BALF) was obtained at 0,6,12,24,48,72 and 96 hours. Controls were healthy volunteers, who had BALF at 24 and 48 hours after methyl-D9-choline infusion. Compositional analysis and enrichment patterns of stable isotope labelling of surfactant phosphatidylcholine (PC) was determined by electrospray ionisation mass spectrometry.
Results: BALF of patients with ARDS consisted of diminished total PC and fractional PC16:0/16:0 concentrations compared to healthy controls. Compositional analysis revealed, reductions in fractional compositions of saturated PC species with elevated levels of longer acyl chain unsaturated PC species. Molecular specificity of newly synthesised PC fraction showed time course variation, with lower PC16:0/16:0 composition at earlier time points, but achieved near equilibrium with endogenous composition at 48 hours after methyl-D9-choline infusion. The enrichment of methyl-D9-choline into surfactant total PC is nearly doubled in patients, with considerable variation between individuals.
Conclusions: This study demonstrate significant alterations in composition and kinetics of surfactant PC extracted from ARDS patients. This novel approach may facilitate biochemical phenotyping of ARDS patients according to surfactant synthesis and metabolism, enabling individualised treatment approaches for the management of ARDS patients in the future.
Figures
References
- Postle AD, Heeley EL, Wilton DC. A comparison of the molecular species compositions of mammalian lung surfactant phospholipids. Comp Biochem Physiol A Mol Integr Physiol. 2001;129:65–73. doi: 10.1016/S1095-6433(01)00306-3.
- Hallman M, Spragg R, Harrell JH, Moser KM, Gluck L. Evidence of lung surfactant abnormality in respiratory failure. Study of bronchoalveolar lavage phospholipids, surface activity, phospholipase activity, and plasma myoinositol. J Clin Invest. 1982;70:673–683. doi: 10.1172/JCI110662.
- Gunther A, Siebert C, Schmidt R, Ziegler S, Grimminger F, Yabut M, Temmesfeld B, Walmrath D, Morr H, Seeger W. Surfactant alterations in severe pneumonia, acute respiratory distress syndrome, and cardiogenic lung edema. Am J Respir Crit Care Med. 1996;153:176–184. doi: 10.1164/ajrccm.153.1.8542113.
- Dushianthan A, Cusack R, Goss V, Postle AD, Grocott MP. Clinical review: exogenous surfactant therapy for acute lung injury/acute respiratory distress syndrome - where do we go from here? Crit Care. 2012;16:238. doi: 10.1186/cc11512.
- Schmidt R, Meier U, Yabut-Perez M, Walmrath D, Grimminger F, Seeger W, Günther A. Alteration of fatty acid profiles in different pulmonary surfactant phospholipids in acute respiratory distress syndrome and severe pneumonia. Am J Respir Crit Care Med. 2001;163:95–100. doi: 10.1164/ajrccm.163.1.9903029.
- Goss V, Hunt AN, Postle AD. Regulation of lung surfactant phospholipid synthesis and metabolism. Biochim Biophys Acta. 1831;2013:448–458.
- Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, Lamy M, Legall JR, Morris A, Spragg R. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med. 1994;149:818–824. doi: 10.1164/ajrccm.149.3.7509706.
- Dushianthan A, Goss V, Cusack R, Grocott MP, Postle AD. Phospholipid composition and kinetics in different endobronchial fractions from healthy volunteers. BMC Pulm Med. 2014;14:10. doi: 10.1186/1471-2466-14-10.
- Postle AD, Henderson NG, Koster G, Clark HW, Hunt AN. Analysis of lung surfactant phosphatidylcholine metabolism in transgenic mice using stable isotopes. Chem Phys Lipids. 2011;164:549–555. doi: 10.1016/j.chemphyslip.2011.04.004.
- Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959;37:911–917. doi: 10.1139/o59-099.
- Simonato M, Baritussio A, Ori C, Vedovelli L, Rossi S, Dalla ML, Rizzi S, Carnielli VP, Cogo PE. Disaturated-phosphatidylcholine and surfactant protein-B turnover in human acute lung injury and in control patients. Respir Res. 2011;12:36. doi: 10.1186/1465-9921-12-36.
- Schmidt R, Markart P, Ruppert C, Wygrecka M, Kuchenbuch T, Walmrath D, Seeger W, Guenther A. Time-dependent changes in pulmonary surfactant function and composition in acute respiratory distress syndrome due to pneumonia or aspiration. Respir Res. 2007;8:55. doi: 10.1186/1465-9921-8-55.
- Bernhard W, Pynn CJ, Jaworski A, Rau GA, Hohlfeld JM, Freihorst J, Poets CF, Stoll D, Postle AD. Mass spectrometric analysis of surfactant metabolism in human volunteers using deuteriated choline. Am J Respir Crit Care Med. 2004;170:54–58. doi: 10.1164/rccm.200401-089OC.
- Wright SM, Hockey PM, Enhorning G, Strong P, Reid KB, Holgate ST, Djukanovic R, Postle AD. Altered airway surfactant phospholipid composition and reduced lung function in asthma. J Appl Physiol. 2000;89:1283–1292.
Source: PubMed